OCGN beat EPS expectations by 26.47%
Aug 08, 2024, 11:32 AM
0.00%
What does OCGN do
Ocugen, Inc., a biopharmaceutical company based in Malvern, Pennsylvania, specializes in therapies for eye diseases and vaccines, including a COVID-19 vaccine candidate for North America. Founded in 2014, the company employs 84 people and is developing platforms for gene and cell therapy, biologics, and mucosal vaccines.
Ocugen (OCGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ocugen's actual EPS was -$0.04, beating the estimate of -$0.05 per share, resulting in a 26.47% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.